Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: Insights from the RELIEVE study's analysis of heavily pretreated patients

This longitudinal retrospective study examined metastatic RCC patients pre-treated with one or more lines of therapy to assess the effectiveness of the lenvatinib plus everolimus combination. The secondary objective was to assess the toxicity profile of this combination. Progression-free survival, time to treatment failure, overall survival, response rate, and toxicity profile was evaluated, as well as the potential relationship between treatment effectiveness and clinical and laboratory parameters.